Hans-Christian Kolberg: Paradigmenwechsel in der Therapie des Ovarialkarzinoms

Renate Haidinger, Brustkrebs Deutschland e.V. im Gespräch mit PD Dr. Hans-Christian Kolberg, Bottrop: 

Besprochene Studien:

Presenter: Antonio González Martín

Niraparib therapy in patients with newly diagnosed advanced ovarian cancer (PRIMA/ENGOT-OV26/GOG-3012 study)


Conclusion: Niraparib significantly improved PFS in pts with newly diagnosed advanced OC, including pts at high risk of progressive disease in the HRDpos subgroup and overall population. No new safety signals were identified. Niraparib should be considered as a treatment option for pts with advanced OC after completion of 1L CT.

NEJM: A. González-Martín and Others: Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer


Presenter: Isabelle Ray-Coquard

Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev 


Conclusion: Addition of olaparib to bev maintenance therapy following 1L PCh plus bev led to a statistically significant and clinically meaningful PFS benefit in pts with advanced OC. The PFS benefit in pts with a tBRCAm and in HRD-positive pts was substantial.


Presenter: Robert Coleman

VELIA/GOG-3005: Integration of veliparib (V) with front-line chemotherapy and maintenance in women with high-grade serous carcinoma of ovarian, fallopian tube, or primary peritoneal origin (HGSC) 


Conclusion: V added to front-line CP and continued as monotherapy maintenance significantly extended PFS in all women with newly diagnosed HGSC without selection according to BRCAm or HRD status, or response to CP. Observed toxicities were consistent with known V safety profile.

NEJMR.L. Coleman and Others: Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer